Search research articles
Contact Us
Filters
Showing results (31-40 of 174) with videos related to
Page
of 18
Sort By:
Health Economics
|
January 4, 2006
Evidence synthesis, parameter correlation and probabilistic sensitivity analysis
A E Ades, Karl Claxton, Mark Sculpher
Pharmacoeconomics
|
March 13, 2002
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study
Mark Sculpher, David Millson, David Meddis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 15, 2006
Probabilistic analysis and computationally expensive models: Necessary and required?
Susan Griffin, Karl Claxton, Neil Hawkins, et al.
Pharmacoeconomics
|
December 15, 2015
Should the Lambda (λ) Remain Silent?
Hossein Haji Ali Afzali, Jonathan Karnon, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 11, 2009
Characterizing structural uncertainty in decision analytic models: a review and application of methods
Laura Bojke, Karl Claxton, Mark Sculpher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 16, 2012
Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions
Simon Walker, Mark Sculpher, Karl Claxton, et al.
Substance Use & Misuse
|
February 14, 2022
Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research
Thomas Patton, Paul Revill, Mark Sculpher, et al.
Intensive Care Medicine
|
May 25, 2002
Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis
Elisabeth Fenwick, Jonathan Wilson, Mark Sculpher, et al.
Health Economics
|
August 3, 2021
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems
Beth Woods, Aimée Fox, Mark Sculpher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 19, 2016
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods, Paul Revill, Mark Sculpher, et al.
Page
of 18
Search research articles
Search
Showing results (31-40 of 174) with videos related to
Sort By:
Page
of 18
Health Economics
|
January 4, 2006
Evidence synthesis, parameter correlation and probabilistic sensitivity analysis
A E Ades, Karl Claxton, Mark Sculpher
Pharmacoeconomics
|
March 13, 2002
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study
Mark Sculpher, David Millson, David Meddis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 15, 2006
Probabilistic analysis and computationally expensive models: Necessary and required?
Susan Griffin, Karl Claxton, Neil Hawkins, et al.
Pharmacoeconomics
|
December 15, 2015
Should the Lambda (λ) Remain Silent?
Hossein Haji Ali Afzali, Jonathan Karnon, Mark Sculpher
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 11, 2009
Characterizing structural uncertainty in decision analytic models: a review and application of methods
Laura Bojke, Karl Claxton, Mark Sculpher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 16, 2012
Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions
Simon Walker, Mark Sculpher, Karl Claxton, et al.
Substance Use & Misuse
|
February 14, 2022
Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research
Thomas Patton, Paul Revill, Mark Sculpher, et al.
Intensive Care Medicine
|
May 25, 2002
Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis
Elisabeth Fenwick, Jonathan Wilson, Mark Sculpher, et al.
Health Economics
|
August 3, 2021
Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems
Beth Woods, Aimée Fox, Mark Sculpher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 19, 2016
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods, Paul Revill, Mark Sculpher, et al.
Page
of 18